Literature DB >> 31677456

Cardiovascular autonomic function and MCI in Parkinson's disease.

Calogero Edoardo Cicero1, Loredana Raciti1, Roberto Monastero2, Giovanni Mostile1, Giulia Donzuso1, Giorgia Sciacca1, Antonina Luca1, Claudio Terravecchia1, Loretta Giuliano1, Roberta Baschi2, Marco Davì2, Mario Zappia1, Alessandra Nicoletti3.   

Abstract

INTRODUCTION: dysautonomic dysfunction and cognitive impairment represent the most disabling non-motor features of Parkinson's Disease (PD). Recent evidences suggest the association between Orthostatic Hypotension (OH) and PD-Dementia. However, little is known on the interactions between cardiovascular dysautonomia and Mild Cognitive Impairment (MCI). We aimed to evaluate the association between cardiovascular dysautonomia and MCI in patients with PD.
METHODS: non-demented PD patients belonging to the PACOS cohort underwent a comprehensive instrumental neurovegetative assessment including the study of both parasympathetic and sympathetic function (30:15 ratio, Expiratory-Inspiratory ratio [E-I] and presence of Orthostatic Hypotension [OH]). Diagnosis of MCI was made according to the MDS criteria level II.
RESULTS: we enrolled 185 PD patients of whom 102 (55.1%) were men, mean age was 64.6 ± 9.7 years, mean disease duration of 5.6 ± 5.5 years with a mean UPDRS-ME score of 31.7 ± 10.9. MCI was diagnosed in 79 (42.7%) patients. OH was recorded in 52 (28.1%) patients, altered 30:15 ratio was recorded in 39 (24.1%) patients and an altered E-I ratio was found in 24 (19.1%) patients. Presence of MCI was associated with an altered 30:15 ratio (adjOR 2.83; 95%CI 1.25-6.40) but not with an altered E-I ratio, while OH was associated only with the amnestic MCI subgroup (OR 2.43; 95% CI 1.05-5.06).
CONCLUSION: in our study sample, MCI was mainly associated with parasympathetic dysfunction in PD.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autonomic system; Cardiovascular dysautonomia; Mild cognitive impairment; Parkinson's disease

Mesh:

Year:  2019        PMID: 31677456     DOI: 10.1016/j.parkreldis.2019.10.023

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson's disease.

Authors:  Sung Hoon Kang; Su Jin Chung; Jungyeun Lee; Seong-Beom Koh
Journal:  Clin Auton Res       Date:  2021-11-29       Impact factor: 4.435

2.  Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort.

Authors:  Antonina Luca; Roberto Monastero; Roberta Baschi; Calogero Edoardo Cicero; Giovanni Mostile; Marco Davì; Vincenzo Restivo; Mario Zappia; Alessandra Nicoletti
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

3.  Executive functioning and serum lipid fractions in Parkinson's disease-a possible sex-effect: the PACOS study.

Authors:  Antonina Luca; Roberto Monastero; Calogero Edoardo Cicero; Roberta Baschi; Giulia Donzuso; Giovanni Mostile; Vincenzo Restivo; Lucia Di Giorgi; Maria Caccamo; Mario Zappia; Alessandra Nicoletti
Journal:  J Neural Transm (Vienna)       Date:  2022-01-13       Impact factor: 3.850

4.  Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease.

Authors:  Claudia Carricarte Naranjo; Connie Marras; Naomi P Visanji; David J Cornforth; Lazaro Sanchez-Rodriguez; Birgitt Schüle; Samuel M Goldman; Mario Estévez; Phyllis K Stein; Anthony E Lang; Herbert F Jelinek; Andrés Machado
Journal:  Clin Auton Res       Date:  2021-07-12       Impact factor: 4.435

5.  Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study.

Authors:  Alessandra Nicoletti; Antonina Luca; Roberta Baschi; Calogero Edoardo Cicero; Giovanni Mostile; Marco Davì; Giuseppe La Bianca; Vincenzo Restivo; Mario Zappia; Roberto Monastero
Journal:  J Neurol       Date:  2020-08-31       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.